000269340 001__ 269340
000269340 005__ 20240926143147.0
000269340 0247_ $$2pmid$$apmid:38599500
000269340 0247_ $$2doi$$a10.1016/j.bbi.2024.04.001
000269340 0247_ $$2ISSN$$a0889-1591
000269340 0247_ $$2ISSN$$a1090-2139
000269340 0247_ $$2altmetric$$aaltmetric:164948658
000269340 037__ $$aDZNE-2024-00509
000269340 082__ $$a150
000269340 1001_ $$00000-0001-7322-1195$$aEndres, Dominique$$b0
000269340 245__ $$aAssociation of rheumatological markers with neuronal antibodies, cerebrospinal fluid, electroencephalography, and magnetic resonance imaging findings in 224 patients with psychotic syndromes
000269340 260__ $$aOrlando, Fla.$$bAcademic Press$$c2024
000269340 3367_ $$2DRIVER$$aarticle
000269340 3367_ $$2DataCite$$aOutput Types/Journal article
000269340 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1714377445_21078
000269340 3367_ $$2BibTeX$$aARTICLE
000269340 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000269340 3367_ $$00$$2EndNote$$aJournal Article
000269340 520__ $$aPsychotic syndromes can have autoimmune-mediated causes in some patients. Thus, this retrospective work aims to investigate the role of rheumatological markers in the development of psychosis.In total, 224 patients with psychotic syndromes receiving a 'rheumatological laboratory screening' (including C-reactive protein [CRP], immunofixation, complement factors, rheumatoid factor [RF], antiphospholipid antibodies [APAs], antineutrophil cytoplasmic antibodies [ANCAs], and antinuclear antibodies [ANAs]) were analyzed. A further diagnostic work-up included investigations of neuronal antibodies and cerebrospinal fluid (CSF), as well as electroencephalography (EEG) and magnetic resonance imaging (MRI) of the brain. ANA testing was routinely performed in all patients using serum on human epithelioma-2 (Hep2) cells, and a subset of patients (N = 73) also underwent tissue-based assays from serum and CSF. The number of cases with autoimmune psychotic syndromes was descriptively collected, and ANA-positive and -negative patients were compared in detail.CRP was elevated in 9 % of patients, immunofixation identified alterations in 8 %, complement factor C3 was decreased in 14 %, RF was elevated in 1 %, APAs were elevated in 7 %, ANCAs were not clearly positive, and ANAs were positive in 19 % (extractable nuclear antigen [ENA] differentiation resulted in positive findings in 14 patients). From the 73 patient samples additionally investigated using tissue-based assays, there were 26 positive results for some kind of ANA (36 %), and overall using both methods, 54 patients (24 %) were considered positive for ANAs. A neuropsychiatric evaluation revealed a possible autoimmune psychotic syndrome in seven patients (3 %) and a probable autoimmune psychotic syndrome in two patients (1 %). ANA-positive patients were more frequently treated with antidepressants (p = 0.040) and had a higher number of somatic comorbidities (p < 0.001). In addition, (chronic) inflammatory MRI lesions (p = 0.008) and focal atrophies (p = 0.012) were found more frequently in ANA-positive than ANA-negative patients.Rheumatological screening led to suspicion of a possible or probable autoimmune psychotic syndrome in 4%. ANAs were associated with MRI pathologies. Therefore, rheumatological processes may contribute to the development of psychotic syndromes in rare cases.
000269340 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000269340 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000269340 650_2 $$2MeSH$$aHumans
000269340 650_2 $$2MeSH$$aPsychotic Disorders: immunology
000269340 650_2 $$2MeSH$$aMale
000269340 650_2 $$2MeSH$$aFemale
000269340 650_2 $$2MeSH$$aAdult
000269340 650_2 $$2MeSH$$aElectroencephalography: methods
000269340 650_2 $$2MeSH$$aMiddle Aged
000269340 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000269340 650_2 $$2MeSH$$aRetrospective Studies
000269340 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000269340 650_2 $$2MeSH$$aBiomarkers: blood
000269340 650_2 $$2MeSH$$aC-Reactive Protein: analysis
000269340 650_2 $$2MeSH$$aC-Reactive Protein: metabolism
000269340 650_2 $$2MeSH$$aAutoantibodies: cerebrospinal fluid
000269340 650_2 $$2MeSH$$aAutoantibodies: blood
000269340 650_2 $$2MeSH$$aAntibodies, Antinuclear: cerebrospinal fluid
000269340 650_2 $$2MeSH$$aAged
000269340 650_2 $$2MeSH$$aBrain: diagnostic imaging
000269340 650_2 $$2MeSH$$aBrain: metabolism
000269340 650_2 $$2MeSH$$aYoung Adult
000269340 650_2 $$2MeSH$$aAutoimmune Diseases: cerebrospinal fluid
000269340 650_2 $$2MeSH$$aNeurons: metabolism
000269340 650_2 $$2MeSH$$aAdolescent
000269340 650_2 $$2MeSH$$aRheumatic Diseases: cerebrospinal fluid
000269340 650_7 $$2Other$$aANA
000269340 650_7 $$2Other$$aAntibody
000269340 650_7 $$2Other$$aAutoimmune psychosis
000269340 650_7 $$2Other$$aComplement
000269340 650_7 $$2Other$$aImmunological
000269340 650_7 $$2NLM Chemicals$$aBiomarkers
000269340 650_7 $$09007-41-4$$2NLM Chemicals$$aC-Reactive Protein
000269340 650_7 $$2NLM Chemicals$$aAutoantibodies
000269340 650_7 $$2NLM Chemicals$$aAntibodies, Antinuclear
000269340 7001_ $$avon Zedtwitz, Katharina$$b1
000269340 7001_ $$aNickel, Kathrin$$b2
000269340 7001_ $$aRunge, Kimon$$b3
000269340 7001_ $$aMaier, Alexander$$b4
000269340 7001_ $$aDomschke, Katharina$$b5
000269340 7001_ $$aSalzer, Ulrich$$b6
000269340 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b7$$udzne
000269340 7001_ $$aVenhoff, Nils$$b8
000269340 7001_ $$avan Elst, Ludger Tebartz$$b9
000269340 773__ $$0PERI:(DE-600)1462491-6$$a10.1016/j.bbi.2024.04.001$$gVol. 119, p. 482 - 493$$p482 - 493$$tBrain, behavior and immunity$$v119$$x0889-1591$$y2024
000269340 8564_ $$uhttps://pub.dzne.de/record/269340/files/DZNE-2024-00509.pdf$$yOpenAccess
000269340 8564_ $$uhttps://pub.dzne.de/record/269340/files/DZNE-2024-00509.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000269340 909CO $$ooai:pub.dzne.de:269340$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000269340 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000269340 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000269340 9141_ $$y2024
000269340 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000269340 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000269340 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000269340 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN BEHAV IMMUN : 2022$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000269340 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bBRAIN BEHAV IMMUN : 2022$$d2023-10-21
000269340 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000269340 980__ $$ajournal
000269340 980__ $$aVDB
000269340 980__ $$aI:(DE-2719)1810003
000269340 980__ $$aUNRESTRICTED
000269340 9801_ $$aFullTexts